Holen Sie sich die Stockscreener-App
7.21
0.56%
0.04
Handel nachbörslich:
7.23
0.02
+0.28%
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus cut to Neutral at Citi on data for mRNA candidate - MSN
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech Gem with 353% Upside Potential? - DirectorsTalk Interviews
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha
Is Arcturus Therapeutics Holdings Inc. stock a buy before product launches - mfd.ru
Arcturus at Guggenheim Biotech Summit: Strategic Advances in mRNA Therapies - Investing.com Canada
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit - MarketBeat
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating - Finviz
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating - MSN
Trading the Move, Not the Narrative: (ARCT) Edition - Stock Traders Daily
Aug Drivers: Is Arcturus Therapeutics Holdings Inc vulnerable to short sellers2025 Price Momentum & Weekly High Conviction Ideas - baoquankhu1.vn
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200-Day Moving AverageHere's Why - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - MSN
Arcturus Therapeutics warns of severe risks from OTC deficiency - Traders Union
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech with 355% Potential Upside - DirectorsTalk Interviews
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(ARCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Should value investors consider Arcturus Therapeutics Holdings Inc.Breakout Watch & Advanced Technical Signal Analysis - mfd.ru
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Roth Mkm - MarketBeat
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating - Investing.com India
Stifel Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $20 - 富途资讯
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Is a 384.87% Upside Potential Within Reach? - DirectorsTalk Interviews
Arcturus Therapeutics Holdings (ARCT) Price Target Decreased by 28.26% to 32.77 - MSN
Arcturus wins FDA fast track status for influenza vaccine - MSN
Price-Driven Insight from (ARCT) for Rule-Based Strategy - Stock Traders Daily
Market Review: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Valuation Update & Fast Moving Market Watchlists - baoquankhu1.vn
Aug EndMonth: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
FEDERATED HERMES, INC. Reduces Stake in Arcturus Therapeutics Ho - GuruFocus
Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility? - simplywall.st
Aug EndMonth: Should I hold or sell Arcturus Therapeutics Holdings Inc stock in 2025July 2025 Update & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Arcturus Therapeutics Holdings (ARCT) Valuation Check As J.P. Morgan Healthcare Conference Presentation Nears - Yahoo Finance
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference - MarketBeat
ARCT: Advancing mRNA therapies for CF and OTC with strong data, regulatory focus, and solid funding - TradingView
Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy? - Yahoo Finance
Ag Plus, Inc. - Ag Plus, Inc.
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 - Yahoo Finance
Will Arcturus Therapeutics Holdings Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Driven Stock Movement Reports - ulpravda.ru
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - Улправда
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
Citigroup Lowers Price Target for ARCT, Maintains Neutral Rating | ARCT Stock News - GuruFocus
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - MarketScreener
MHRA approves Kostaive mRNA COVID-19 vaccine - The Pharma Letter
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):